Curtis SD, Panda S, Li A, Xu H, Bai Y, Ogihara I, O’Reilly E, Wang Y, Dobbyn L, Popoli M, Ptak J, Nehme N, Silliman N, Tie J, Gibbs P, Ho-Pham LT, Tran BNH, Tran TS, Nguyen TV, Irajizad E, Goggins M, Wolfgang CL, Wang T-L, Shih I-M, Fader A, Lennon AM, Hruban RH, Bettegowda C, Gilbert L, Kinzler KW, Papadopoulos N, Vogelstein B, Vogelstein JT, Douville C. Minimizing and quantifying uncertainty in AI-informed decisions: Applications in medicine. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(34):10.1073/pnas.2424203122
Curtis SD, Liu T, Bai Y, Wang Y, Panda S, Li A, Xu H, O’Reilly E, Dobbyn L, Popoli M, Ptak J, Silliman N, Thoburn C, Tie J, Gibbs P, Ho-Pham LT, Tran BNH, Tran TS, Nguyen TV, Konig MF, Petri M, Rosen A, Mecoli CA, Shah AA, Mulder F, van Es N, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein JT, Vogelstein B, Douville C, Klok FA, Beyer-Westendorf J, Jara-Palomares L, Ageno W, Peters MJL, Delluc A, Best M, Guman N, Otten H-M, Mulder F, van Es N. Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(34):10.1073/pnas.2426890122
Michael M, Wong R, Gill S, Strickland AH, Pavlakis N, Shapiro JD, Link E, Farrell M, Ngan SY, Tie J, Heriot AG, Goldstein D, Mitchell C, Roth S, Wilson K, Mui M, Ramsay RG, Segelov E. The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.Clinical Cancer Research. 2025;31(16):10.1158/1078-0432.ccr-25-0705
Allan Z, Wang Y, Tie J, Tebbutt N, Clemons N, Papadolpoulos N, Kinzler K, Vogelstein B, Liu DSH. 091. MULTI-OMICS EVALUATION OF PERITONEAL FLUID IN GASTROESOPHAGEAL CANCER: RESULTS FROM INTERIM ANALYSIS. Diseases of the Esophagus. 2025;38(Supplement_1):10.1093/dote/doaf061.006
Desmond B, Alukaidey L, Allan Z, Cabalag C, Clemons NJ, Michael M, Tie J, Tebbutt N, Duong CP, Liu DS. Neoadjuvant intraperitoneal chemotherapy in high-risk and cytology positive gastric cancer: a systematic review. Surgical Oncology. 2025;61:10.1016/j.suronc.2025.102237
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, Kukard C, Jayawardana M, Silva SSM, Alexander M, Tie J, Galettis P, Martin JH. Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial. British Journal of Clinical Pharmacology. 2025;91(7):10.1002/bcp.70006
Zaman FY, Orchard SG, Polekhina G, Gibbs P, Bernstein WB, Macrae F, Tie J, Millar J, Gately L, Rodríguez LM, van Londen GJ, Mar V, Hiscutt E, Adler N, Kent A, Ong WL, Haydon A, Warner E, Chan AT, Zalcberg J. Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. Journal of the National Cancer Institute. 2025;:10.1093/jnci/djaf145
Burge ME, Espinoza D, Sjoquist KM, Siu DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, Thaker DA, Srivastav R, Abdi E, Strickland A, Segelov E, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2025;24(2):10.1016/j.clcc.2024.11.003
Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, Burge ME, Harris SJ, Lee B, Lynam JF, O’Callaghan CJ, Breadner DA, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3503
McLachlan S-A, Mostafa R, Sharpe L, Burge ME, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M, Chantrill LA, Lundy J, Wong ZW, Wong R, Joshi S, Saqib A, Karikios DJ, Gibbs P, Tie J. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.11125
